Journal
JOURNAL OF IMMUNOLOGY
Volume 179, Issue 5, Pages 3178-3186Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.179.5.3178
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI 62388, AI 49344, AI 44970] Funding Source: Medline
Ask authors/readers for more resources
Decay-accelerating factor (DAF, CD55) is a GPI-anchored membrane protein that regulates complement activation on autologous cells. In addition to protecting host tissues from complement attack, DAF has been shown to inhibit CD4(+) T cell immunity in the setting of model Ag immunization. However, whether DAF regulates natural T cell immune response during pathogenic infection is not known. We describe in this study a striking regulatory effect of DAF on the CD8(+) T cell response to lymphocytic choriomeningitis virus (LCMV) infection. Compared with wild-type mice, DAF knockout (Daf-1-1-) mice had markedly increased expansion in the spleen of total and viral Ag-specific CD8(+) T cells after acute or chronic LCMV infection. Splenocytes from LCMV-infected Daf-1-1- mice also displayed significantly higher killing activity than cells from wild-type mice toward viral Ag-loaded target cells, and Daf- 1 (-/-) mice cleared LCMV more efficiently. Importantly, deletion of the complement protein C3 or the receptor for the anaphylatoxin C5a (C5aR) from Daf-1-1- mice reversed the enhanced CD8' T cell immunity phenotype. These results demonstrate that DAF is an important regulator of CD8' T cell immunity in viral infection and that it fulfills this role by acting as a complement inhibitor to prevent virus-triggered complement activation and C5aR signaling. This mode of action of DAF contrasts with that of CD59 in viral infection and suggests that GPI-anchored membrane complement inhibitors can regulate T cell immunity to viral infection via either a complement-dependent or -independent mechanism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available